MedTrace Logo

A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

NCT06605703 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2026-04-13

No results posted yet for this study

Summary

The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.

Conditions

Interventions

BEHAVIORAL

WW Clinic

Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.

DRUG

Bupropion-Naltrexone

Bupropion-Naltrexone

DRUG

Bupropion-Naltrexone-Metformin

Bupropion-Naltrexone-Metformin

Sponsors & Collaborators

  • WW International Inc

    lead INDUSTRY

Principal Investigators

  • Kara Marlatt, PhD, MPH · WW International Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-18
Primary Completion
2026-02-05
Completion
2026-02-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06605703 on ClinicalTrials.gov